AR016200A1 - THE USE OF A COMPOSITION THAT INCLUDES ONE OR MORE COMPOUNDS CONTAINING SULFUR FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO INCREASE THE PERMEABILITY OF THE HUMAN CORN FABRIC, AND A KIT THAT INCLUDES SUCH COMPOSITION - Google Patents

THE USE OF A COMPOSITION THAT INCLUDES ONE OR MORE COMPOUNDS CONTAINING SULFUR FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO INCREASE THE PERMEABILITY OF THE HUMAN CORN FABRIC, AND A KIT THAT INCLUDES SUCH COMPOSITION

Info

Publication number
AR016200A1
AR016200A1 ARP990101431A ARP990101431A AR016200A1 AR 016200 A1 AR016200 A1 AR 016200A1 AR P990101431 A ARP990101431 A AR P990101431A AR P990101431 A ARP990101431 A AR P990101431A AR 016200 A1 AR016200 A1 AR 016200A1
Authority
AR
Argentina
Prior art keywords
composition
permeability
kit
manufacture
increase
Prior art date
Application number
ARP990101431A
Other languages
Spanish (es)
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of AR016200A1 publication Critical patent/AR016200A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El uso de una composicion que comprende uno o más compuestos que contienen azufre para la fabricacion de un medicamento util para aumentar la permeabilidaddel tejido corneo humano a los agentes activos, caracterizado porque consiste en una cantidad efectiva de uno o más compuestos que contienen azufre al tejidocorneo humano durante un período de tiempo suficiente para aumentar la permeabilidad del tejido corneo humano a los agentes activos, y un kit que incluye dichacomposicion.The use of a composition comprising one or more sulfur-containing compounds for the manufacture of a medicament useful for increasing the permeability of human corneal tissue to active agents, characterized in that it consists of an effective amount of one or more sulfur-containing compounds to the corneal tissue. human for a period of time sufficient to increase the permeability of the human corneal tissue to the active agents, and a kit that includes said composition.

ARP990101431A 1998-03-31 1999-03-30 THE USE OF A COMPOSITION THAT INCLUDES ONE OR MORE COMPOUNDS CONTAINING SULFUR FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO INCREASE THE PERMEABILITY OF THE HUMAN CORN FABRIC, AND A KIT THAT INCLUDES SUCH COMPOSITION AR016200A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8021298P 1998-03-31 1998-03-31

Publications (1)

Publication Number Publication Date
AR016200A1 true AR016200A1 (en) 2001-06-20

Family

ID=22155965

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101431A AR016200A1 (en) 1998-03-31 1999-03-30 THE USE OF A COMPOSITION THAT INCLUDES ONE OR MORE COMPOUNDS CONTAINING SULFUR FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO INCREASE THE PERMEABILITY OF THE HUMAN CORN FABRIC, AND A KIT THAT INCLUDES SUCH COMPOSITION

Country Status (4)

Country Link
AR (1) AR016200A1 (en)
AU (1) AU3212099A (en)
CO (1) CO5070608A1 (en)
WO (1) WO1999049895A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
GB0511499D0 (en) * 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
EP1891960B1 (en) * 2006-08-17 2009-09-30 Klever Mode, S.L. Pharmaceutical formula for treating skin disease
EP2575829A4 (en) * 2010-06-07 2014-04-30 Topical Pharma Ab Kit for the treatment of onychomycosis by nitric oxide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956467A (en) * 1988-04-01 1990-09-11 American Cyanamid Company Nucleophilic tertiary organophosphines
IL97012A0 (en) * 1990-01-30 1992-03-29 Gist Brocades Nv Topical preparations for treating human nails
IT1249047B (en) * 1991-02-21 1995-02-11 Zambon Spa PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
FR2681782B1 (en) * 1991-09-26 1993-12-17 Oreal COMPOSITION FOR THE TREATMENT OF NAILS CONTAINING A SULFUR AMINOACID.
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails

Also Published As

Publication number Publication date
CO5070608A1 (en) 2001-08-28
WO1999049895A3 (en) 1999-11-18
WO1999049895A2 (en) 1999-10-07
AU3212099A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
ES2159591T3 (en) COMPOSITION OF CONTROLLED RELEASE.
SV2002000245A (en) SUBSTITUTED OXAZOLIDINONES AND ITS USE REF. READ 34122-SV
ES2035259T3 (en) ABSORBENT COMPOUND.
DE60117043D1 (en) TREATMENT OF MUCOSITIS
BR0009830A (en) Skin care compositions containing a combination of active substances for skin care
NZ597106A (en) Ophthalmic compositions comprising carnitine and methods for treating eyes
KR920019342A (en) Bone Disease Treatment
BRPI0820800B8 (en) implantable medical device for controlled drug release
AR018286A1 (en) PHARMACEUTICAL COMPOSITION THAT IN QUALITY OF ACTIVE PRINCIPLE CONTAINS THE ASFCIATION OF METFORMIN AND FIBRATE, AND THE USE OF THIS ASSOCIATION TO PREPARE MEDICATIONS
BRPI0017528B8 (en) use of a composition containing ketotifen salt
DE69921318D1 (en) SURFACTANT FOR OUTSIDE SKIN PREPARATIONS AND THESE CONTAINING SKIN PREPARATIONS FOR EXTERNAL USE
CO5001019A1 (en) EMULSIONABLE COMPOSITION FOR THE REPRESSION OF INSECTS, WHICH IS DERIVED FROM THE TYPE OF PHENYLPIRAZOLS REPLACED IN POSITION 1, AND DO NOT FAVOR THE FORMATION OF CRYSTALS
TR200400526T4 (en) Lipoxin A4 and analogues for the treatment of dry eye
ES2011232T3 (en) PHARMACEUTICAL COMPOSITIONS OF PIROXICAM IN AQUEOUS SOLUTIONS AND PROCEDURE FOR ITS PREPARATION.
BR9814299A (en) Aminobiguanides and their use for contact disinfectants and to preserve pharmaceutical compositions
BR0304298A (en) Composition containing a cosmetically active organic acid and a vegetable product
BR0111678A (en) Medicinal compositions containing propenone derivatives
AR032872A1 (en) COMPOSITION TO CLEAR THE SKIN AND APPLICATION METHOD
GT200400220A (en) PRODUCTS FOR AXILS WITH SUPERABSORBENT COMPONENT.
HK1110768A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
DE60031016D1 (en) Use of antiseptics for the preparation of medicaments for the prophylaxis and treatment of inflammation in the interior of the human body
AR004077A1 (en) A PARTICULARLY COSMETIC COMPOSITION, AND MORE PARTICULARLY FOR THE PERMANENT DEFORMATION OF KERATINIC FIBERS.
AR016200A1 (en) THE USE OF A COMPOSITION THAT INCLUDES ONE OR MORE COMPOUNDS CONTAINING SULFUR FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO INCREASE THE PERMEABILITY OF THE HUMAN CORN FABRIC, AND A KIT THAT INCLUDES SUCH COMPOSITION
SE7512231L (en) STERILIZER
BR9913982A (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases